Donations After Reentry

Slides:



Advertisements
Similar presentations
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Advertisements

HCV Assays: Impact on HCV Studies & Update on HCV blood bank protocol.
Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
6/03/031 Hepatitis C –Update Laboratory Issues Hema Kapoor MD. SM Virology Section Manager Bureau of Laboratories Michigan Department of Community Health.
Development of Guidance Documents Jennifer Scharpf, M. P. H
An Automobile Accident Victim Up to 50 units of red blood cells An Organ Transplant Recipient Up to 40 units of red blood cells 30 units of platelets 25.
CBER Whole Blood and Blood Component Labeling Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.
Ad Hoc Disease Transmission Advisory Committee Spring 2015.
F. Kourgia, M. Vini, E. Zervou
NAT Yield from Real Time Testing of Organ Donors for HIV-1 RNA and HCV RNA Safer Organs and No False Positive Results Claudia Chinchilla-Reyes, MB(ASCP)1,
Guidelines for Laboratory Testing and Result Reporting for Antibody to Hepatitis C Virus Miriam J. Alter, Ph.D. Division of Viral Hepatitis Centers for.
Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
Prevalence and risk relationships of tattoo, acupuncture and skin/body piercing histories among American Red Cross blood donors Sharyn Orton, MSPH, PhD.
Transfusion of Blood Product History: 1920:Sodium citrate anticoagulant(10 days storage) 1958: Plastic bag of transfusion 1656: Initial theory and.
Immunohematology (Blood Bank) CLS 245. What is Immunohematology? It is the study of Antigen-Antibody reaction as they relate to blood disorder.
CBER U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.
Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
BioLife Plasma Services Experience with HBV NAT Testing
Inputs to a case-based HIV surveillance system. Objectives  Review HIV case definitions  Understand clinical and immunologic staging  Identify the.
And the order changeth …. Evolving protocols for TTI testing
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
CBER Review Considerations on Source Plasma Vaccination Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
CBER 1 Establishment Submissions Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
Implementing a Rapid HIV Testing Guideline for L&D NNEPQIN April 30, 2007.
Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.
Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008.
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
Revision Process for the PHS Guideline for Reducing HIV, HBV and HCV Transmission through Solid Organ Transplantation Matthew J. Kuehnert, M.D. Office.
Apheresis Blood Components
Some Observations on the Deferral of Volunteer Blood Donors for nvCJD Risk Merlyn H. Sayers, M.B., B.Ch., Ph.D. Carter BloodCare Dallas/Fort Worth, Texas.
Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.
1 B19 Testing of Plasma for Fractionation: Current Thinking Mei-ying W Yu, PhD Division of Hematology CBER/FDA SoGAT XVII May 26-27, 2004.
Awesome Variances “First break all the rules” Carolyn Te Young & Jed Gorlin ABC 7/04.
Abbreviated Donor History Questionnaire: Background and Introduction Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 2005.
Our tryst with Nucleic Acid Testing Dolly Daniel, Dept of Transfusion Medicine, CMC, Vellore.
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
Management of Donors and Units that Test HBV NAT Positive: Current Considerations July 21, 2005 BPAC Meeting Robin Biswas, M.D. FDA/CBER/OBRR/DETTD.
Update Rapid HIV Test Approval Requirements and Standards BPAC September 15, 2000 Kimber Poffenberger, Ph.D.
CBER Source Plasma Labeling Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
Modeling Risk of vCJD in US Donors – Residual Risk and Efficiency of Donor Deferral Alan E. Williams, Ph.D. Director, Division of Blood Applications Office.
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
West Nile Virus (WNV) and Donors of Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/Ps) Melissa A. Greenwald, MD Division of Human Tissues.
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
Results Methods A Five-Year Snapshot of Our Hereditary Hemochromatosis Program: A Work in Progress P Davenport 1, D Echols 1, J Giacoletti 1, L Sutor 1,2,
HIV INFECTION: Diagnostic strategy for patients with suspected HIV infection. This new testing algorithm, recommended in 2015 by the Centers for Disease.
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
TRANSFUSION: Blood donation and preparation of blood components
Organ Donor Infectious Disease Testing Education
Communications Protocols: The Good Faith Process
Erythrocytapheresis.
California Clinical Laboratory Association
POST EXPOSURE PROPHYLAXIS IN HCW
Case Definition: HEPATITIS C
OPTN Kidney Paired Donation (KPD) Histocompatibility Testing Policies
INTEGRATING HIV AND HCV TESTING.
FACTORS ASSOCIATED WITH RECEIPT OF HEPATITIS B VACCINE AMONG HIGH RISK ADULTS NATIONAL HEALTH INTERVIEW SURVEY, 2000 Nidhi Jain MD MPH The topic of my.
CMV Working Group Update to NAC April 2016.
NUCLEIC ACID AMPLIFICATION TESTING DETECTS HIV TRANSMISSION RISK IN SEROLOGICALLY- TESTED BLOOD DONOR UNITS. |Presented by Miss Shemau Muniru| Authors:
OPTN Kidney Paired Donation (KPD) Histocompatibility Testing Policies
Alternatives for evaluating daughter performance of progeny-test bulls between official evaluations Abstr. #10.
A CASE SERIES OF DISCORDANT LABORATORY RESULTS WITH RAPID HIV TESTING
Challenges for Blood Donor Confirmatory Testing Algorithms
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

Donations After Reentry Results of Reentry Processes Based on New 2010 Final FDA Guidelines P Davenport2, L Sutor1, J Chiu2 1University of Texas Southwest Medical Center Dallas, TX and 2Carter BloodCare, Bedford, TX Background Methods Conclusion Final FDA guidelines for reentering donors deferred for HIV and HCV antibody or nucleic acid tests (NAT) were published in May 2010. Under separate, new final guidelines, a process for reentering donors deferred for antibodies to hepatitis B core antigen (anti-HBc) was also published. After implementing these guidelines at our blood center, the results of the new processes over a period of time are presented. These are compared to results from older approved HIV/HCV reentry processes. We also looked at the number of donations the previously deferred donors made after they were reentered to eligible status to assess donor motivation for reentry and to determine whether our efforts were worthwhile. Contact letters were sent to 288 donors who previously expressed interest in reentry for HIV or HCV, but were not eligible according to older guidelines (indeterminate HIV-1 Western Blot or HCV RIBA) or HIV-1 p24 antigen. A smaller group of donors (72), deferred for more than one positive anti-HBc, was sent contact letters for potential reentry. Donors contacted for anti-HBc reentry were limited to those who had specifically requested reentry testing when available, or had non-sequential repeat reactive (RR) anti-HBc results (non-reactive donations between RR donations). Respondents from both contacted groups and other interested donors deferred for false positive results were tested according to the new guidelines, and records reviewed for eligibility. Donation records of reentered donors were later reviewed to determine donations made after reentry. Response to the contact letters was surprisingly positive considering that many of the donors had been deferred for 10 years or more. We considered the success rates (eligible for reentry) very positive, especially for HIV reentry, compared to those of an earlier study based on reentry by the old 1992 HIV reentry process. We concluded that the reentry efforts were well worthwhile and that the majority of donors were motivated by desire to resume donating since more than half returned to so, many as repeat donors. Others did not return perhaps because not enough time had passed, or because they may only have wanted the positive result mark removed from their record. Additional data gathered over a longer period of time would yield more conclusive information. Comparison of Reentry Processes Reentry Process Number Tested Reentered Denied 2010 HIV 79 75 (94.9 %)) 4 1992 HIV 94 44 (47%) 50 2010 HCV 72 46 (63.9%) 26 1993 HCV 29 (58%) 21 2010 anti-HBc 28 19 (67.8%) 9 Results References Of all contact letters sent for potential HIV/HCV/anti-HBc reentry, 35.1% of the donors responded. After all donors were tested by the new guidelines and records reviewed, 94.9% of donors returning for HIV, 63.9% for HCV and 67.8% for anti-HBc reentry were eligible. Lower reentry rates for HCV and anti-HBC were almost entirely due to recurring false positive or repeat reactive results. Within approximately 1 year after the new reentry processes were implemented, 61% of the reentered donors had attempted to donate at least once and 242 whole blood or apheresis products had been collected. 1. FDA Guidance for Industry: Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry. May 2010. 2. Analysis of the Value of Donor Reentry for False Positive HIV-1/2 Results. K J Land, P Davenport, 2006 3. FDA Memorandum to Blood Establishments: Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV), August 1993 FDA Memorandum to Blood Establishments: Revised Recommendations for the Prevention of Human Immunodeficiency Virus (HIV) Transmission by Blood and Blood Products. April 1992 Donations After Reentry Tested Donors Reentered Donors Returned to Donate After Reentry Whole Blood/Apheresis Products Collected Within ~ 1 Year 179 140 86 (61%) 242 Carter BloodCare, AABB 2011